Regulus Therapeutics Azioni (NASDAQ: RGLS)

Ultime notizie per Regulus Therapeutics (NASDAQ:RGLS) Azioni

Regulus Therapeutics

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Novartis building

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

RGLS

Offerta cash con premio elevato per azienda biofarmaceutica specializzata in malattie renali. Pagamento aggiuntivo legato a milestone.

Novartis acquisisce società americana e il titolo schizza del 133%!

Regulus Therapeutics Inc

REGULUS RES INC by Regulus Resources, Inc.

Regulus Resources Inc

Jones Trading analyst Catherine Novack downgrades Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) from Buy to Hold and lowers the price target from $8 to $7.

Downgrades

Price Target

Analyst Ratings

Jones Trading Downgrades Regulus Therapeutics to Hold, Lowers Price Target to $7

Canaccord Genuity analyst Whitney Ijem downgrades Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) from Buy to Hold and lowers the price target from $28 to $11.

Canaccord Genuity Downgrades Regulus Therapeutics to Hold, Lowers Price Target to $11

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares increased by 132.5% to $7.83 during Wednesday's regular session. The company's market cap stands at $519.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 71.13% to $54.08. The company's market cap stands at $703.7 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares increased by 62.72% to $2.62. The company's market cap stands at $12.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) shares moved upwards by 30.18% to $6.9. The market value of their outstanding shares is at $334.8 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock increased by 24.26% to $7.06. The company's market cap stands at $78.3 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 20.73% to $1.31. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock declined by 38.7% to $71.69 during Wednesday's regular session. The company's market cap stands at $2.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock decreased by 23.59% to $2.83. The company's market cap stands at $2.3 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) stock declined by 21.78% to $7.76. The market value of their outstanding shares is at $25.1 million. </li>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) stock fell 21.53% to $1.75. The market value of their outstanding shares is at $52.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares decreased by 15.63% to $1.08. The company's market cap stands at $103.4 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares fell 15.54% to $0.25. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABEO

BCLI

CLRB

COEP

IMUX

NAOV

NTRB

ZYXI

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.
The Dow traded down 0.47% to 40,335.51 while the NASDAQ dipped 1.22% to 17,248.37. The S&amp;P 500 also fell, dropping, 0.83% to 5,514.48.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/45098110/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a>
Leading and Lagging Sectors Consumer staples shares rose by 0.3% on Wednesday.
In trading on Wednesday, energy stocks dipped by 3.3%.
Top Headline
The EIA reported that U.S. crude oil inventories declined by 2.696 million barrels in the week ended April 25, versus market estimates of a 0.39 million barrel gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares shot up 131% to $7.78 after the company announced it entered into an agreement to be acquired by Novartis AG for $7 in cash per share.</li>
<li>Shares of Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>)got a boost, surging 45% to $1.23 after the company announced the sale of its Smart Repair Pro business for $11.8 million.</li>
<li>INVO Fertility, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares were also up, gaining 75% to $2.8150 after the company announced fourth-quarter results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vicor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) shares dropped 20% to $41.33 after the company reported first-quarter financial results and missed its EPS and sales estimates.</li>
<li>Shares of GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) were down 40% to $70.47 after the company posted first-quarter results.</li>
<li>Wabash National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) was down, falling 28% to $7.13 after the company reported worse-than-expected first-quarter financial results and issued FY25 guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 3.4% to $59.75 while gold traded down 0.6% at $3,314.70.
Silver traded down 2.1% to $32.865 on Wednesday, while copper fell 5.7% to $4.5935.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.46%, Germany's DAX 40 rose 0.32% and France's CAC 40 gained 0.50%. Spain's IBEX 35 Index fell 0.59%, while London's FTSE 100 rose 0.37%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei gaining 0.57%, China's Shanghai Composite falling 0.23%, Hong Kong's Hang Seng Index gaining 0.51% and India's BSE Sensex falling 0.06%.
Economics
<ul>
<li>The U.S. economy shrank at an annualized rate of 0.3% during the first quarter of 2025, following a 2.4% growth in the prior quarter.</li>
<li>Private business in the U.S. created 62,000 workers to their payrolls in April following a revised 147,000 payrolls in the earlier month.</li>
<li>The Chicago PMI declined to 44.6 in April versus 47.6 in the previous month.</li>
<li>The EIA reported that U.S. crude oil inventories declined by 2.696 million barrels in the week ended April 25, versus market estimates of a 0.39 million barrel gain.</li>
<li>U.S. pending home sales rose 6.1% month-over-month in March, compared to markt estimates of 1%.</li>
<li>The core PCE price index came in unchanged from the previous month in March.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/media/25/04/45098332/jim-cramer-this-tech-stock-is-not-great-not-bad-alaska-air-can-still-go-lower">Jim Cramer: This Tech Stock Is &#8216;Not Great, Not Bad&#8217;, Alaska Air Can Still Go Lower</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

JFBR

VICR

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) agreed to acquire Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) on Wednesday for an initial payment of $7.00 per share in <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cash or $0.8 billion</a>.
The upfront cash portion of the consideration represents a premium of 274% to Regulus&#8217; 60-day volume-weighted average stock price and 108% to Regulus&#8217; closing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45095629/regulus-therapeutics-enters-into-agreement-to-be-acquired-by-novartis-ag" rel="noreferrer noopener">price on&nbsp;April 29, 2025</a>.
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics for severe renal disease and autosomal dominant polycystic kidney disease (ADPKD).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" rel="noreferrer noopener">Novartis Q1 Earnings Beat Street View, CEO &#8216;Confident&#8217; In Delivering Upgraded Guidance</a>
The lead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial.
In addition, Regulus shareholders will receive a contingent value right (CVR) providing for payment of&nbsp;$7.00&nbsp;per share, contingent upon the achievement of a milestone regarding the regulatory approval of Regulus&#8217; lead product candidate, farabursen.
If the milestone is achieved, total consideration, including the CVR, would be approximately&nbsp;$1.7 billion.
The transaction is expected to close in the second half of 2025. Regulus will continue to operate as a separate and independent company.
In March, Regulus Therapeutics released topline results from all patients in the fourth cohort in its Phase&nbsp;1b&nbsp;MAD study of farabursen <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44519887/regulus-therapeutics-stock-shoots-higher-after-positive-results-from-investigational-drug-for-rare-type-of-kidney-disease" rel="noreferrer noopener">(RGLS8429) for ADPKD</a>.
Cohort 4 data highlights:
<ul>
<li>Increases in urinary PC1 and PC2 levels were similar to cohort 3 and reached a similar level of statistical significance compared to placebo (PC1 p=0.026; PC2 p=0.014).</li>
<li>The mean htTKV growth rate over 4 months was 0.05%, while placebo subjects in the trial experienced a mean growth rate of 2.58%.</li>
<li>Changes in htTKV were highly correlated with changes in renal cyst volume, suggesting farabursen directly impacts disease progression by limiting abnormal cyst growth.</li>
</ul>
Novartis strengthened its kidney disease portfolio after the U.S. Food and Drug Administration (FDA) granted accelerated approval for&nbsp;Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44631273/novartis-secures-third-fda-approval-for-its-kidney-disease-portfolio-in-one-year" rel="noreferrer noopener">rapid disease progression</a>.
This is Novartis' third U.S. approval for its kidney disease portfolio in the last year. Fabhalta&nbsp;was granted FDA approval in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44544720/fda-oks-novartis-prostate-cancer-treatment-triples-eligible-patient-pool" rel="noreferrer noopener">C3 glomerulopathy in&nbsp;March 2025</a>&nbsp;and accelerated approval in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40254535/fda-approves-expanded-use-of-novartis-rare-disease-drug-fabhalta-for-kidney-disease" rel="noreferrer noopener">IgAN in&nbsp;August 2024</a>.
Price Action: RGLS stock is up 132.9% at $7.85 during the premarket session at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45084149/trade-desk-wins-analyst-conviction-on-streaming-growth-over-amazon-competition" target="_blank" rel="noreferrer noopener">Analyst Says Trade Desk Can Shake Off Challenges, Ride Streaming&#8217;s Next Big Wav</a></li>
</ul>
Photo: Shutterstock

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

U.S. stocks traded lower this morning, with the Dow Jones index falling over 600 points on Wednesday.
Following the market opening Wednesday, the Dow traded down 1.63% to 39,867.25 while the NASDAQ dipped 2.71% to 16,987.60. The S&amp;P 500 also fell, dropping, 2.07% to 5,445.87.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/45098110/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a>
Leading and Lagging Sectors Health care shares fell by just 0.3% on Wednesday.
In trading on Wednesday, consumer discretionary dipped by 3.5%.
Top Headline 
Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) reported downbeat first-quarter 2025 results.
Total sales and revenue for the quarter declined 9.8% year-over-year to $14.25 billion, missing the consensus of $14.66 billion. CAT's adjusted earnings were $4.24 per share, compared to $5.60 a year ago and below the consensus of $4.35.
Caterpillar expects second-quarter sales and revenues to be similar to 2024. The adjusted operating profit margin is expected to be lower than YoY, mainly due to lower price realization before considering tariff impact.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares shot up 130% to $7.76 after the company announced it entered into an agreement to be acquired by Novartis AG for $7 in cash per share.</li>
<li>Shares of Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>)got a boost, surging 71% to $1.45 after the company announced the sale of its Smart Repair Pro business for $11.8 million.</li>
<li>INVO Fertility, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares were also up, gaining 63% to $2.61 after the company announced fourth-quarter results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) shares dropped 53% to $0.3574.</li>
<li>Shares of GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) were down 36% to $75.14 after the company posted first-quarter results.</li>
<li>Wabash National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNC#NYSE">WNC</a>) was down, falling 26% to $7.33 after the company reported worse-than-expected first-quarter financial results and issued FY25 guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 1.1% to $59.75 while gold traded down 0.6% at $3,313.80.
Silver traded down 2% to $32.925 on Wednesday, while copper fell 6.1% to $4.5770.
Euro zone
European shares were lower today. The eurozone's STOXX 600 slipped 0.2%, Germany's DAX 40 fell 0.4% and France's CAC 40 declined 0.2%. Spain's IBEX 35 Index fell 1.9%, while London's FTSE 100 fell 0.1%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei gaining 0.57%, China's Shanghai Composite falling 0.23%, Hong Kong's Hang Seng Index gaining 0.51% and India's BSE Sensex falling 0.06%.
Economics
<ul>
<li>The U.S. economy shrank at an annualized rate of 0.3% during the first quarter of 2025, following a 2.4% growth in the prior quarter.</li>
<li>Private business in the U.S. created 62,000 workers to their payrolls in April following a revised 147,000 payrolls in the earlier month.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/media/25/04/45098332/jim-cramer-this-tech-stock-is-not-great-not-bad-alaska-air-can-still-go-lower">Jim Cramer: This Tech Stock Is &#8216;Not Great, Not Bad&#8217;, Alaska Air Can Still Go Lower</a> </li>
</ul>
Photo via Shutterstock

S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results

WIIM

Regulus Therapeutics shares are trading higher after the company announced it entered into an agreement to be acquired by Novartis AG for $7 in cash per share.

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares increased by 134.1% to $7.89 during Wednesday's pre-market session. The company's market cap stands at $522.6 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares rose 39.75% to $2.25. The company's market cap stands at $11.1 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock increased by 24.16% to $3.7. The company's market cap stands at $139.3 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 21.47% to $0.02. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock increased by 18.72% to $0.2. The market value of their outstanding shares is at $5.2 million. </li>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) shares moved upwards by 17.44% to $2.76. The company's market cap stands at $216.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock declined by 37.4% to $1.91 during Wednesday's pre-market session. The company's market cap stands at $258.3 million. </li>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares decreased by 28.19% to $84.0. The market value of their outstanding shares is at $2.3 billion. The company's, Q1 earnings came out today. </li>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares decreased by 21.88% to $1.0. The company's market cap stands at $95.8 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 18.21% to $0.25. The market value of their outstanding shares is at $3.4 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) stock declined by 13.03% to $5.21. The company's market cap stands at $117.5 million. </li>
<li>Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) shares decreased by 12.35% to $8.21. The market value of their outstanding shares is at $564.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARVN

CYCC

GCTK

INNV

LGMK

NTHI

PHLT

SERA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will acquire Regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. The upfront cash portion of the consideration represents a premium of 274 percent to Regulus' 60-day volume-weighted average stock price and 108 percent to Regulus' closing price on April 29, 2025. In addition, Regulus shareholders will receive a contingent value right (CVR) providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus' lead product candidate, farabursen. Total consideration including the CVR, if the milestone is achieved, would be approximately $1.7 billion. The transaction has been unanimously approved by the Boards of Directors of both companies.
Completion of the transaction is expected in the second half of 2025, subject to the satisfaction or waiver of customary closing conditions, including the tender of shares representing at least a majority of the total number of Regulus' outstanding shares, and other customary closing conditions and regulatory clearance. Until that time, Regulus will continue to operate as a separate and independent company.
&nbsp;

Novartis To Buy Regulus Therapeutics For $7.00/Shr In Cash, With Potential To Receive Addl $7.00/Shr In Cash Through Contingent Value Right, For Total Equity Value Of Up To About $1.7B

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Wells Fargo analyst Yanan Zhu upgrades Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) from Equal-Weight to Overweight and raises the price target from $3 to $6.

Upgrades

Wells Fargo Upgrades Regulus Therapeutics to Overweight, Raises Price Target to $6

<h3>Gainers</h3>
<ul>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock increased by 79.1% to $0.95 during Thursday's regular session. The market value of their outstanding shares is at $25.4 million. </li>
<li>Nkarta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTX#NASDAQ">NKTX</a>) stock increased by 55.41% to $2.13. The company's market cap stands at $150.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) stock moved upwards by 53.87% to $1.99. The market value of their outstanding shares is at $131.4 million. </li>
<li>Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares increased by 43.33% to $70.19. The company's market cap stands at $3.0 billion. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) stock rose 29.05% to $9.95. The market value of their outstanding shares is at $86.5 million. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares rose 21.52% to $2.94. The company's market cap stands at $9.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares declined by 29.7% to $0.72 during Thursday's regular session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares declined by 26.14% to $0.56. The market value of their outstanding shares is at $19.8 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) shares declined by 23.49% to $2.9. The company's market cap stands at $55.9 million. </li>
<li>EXoZymes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXOZ#NASDAQ">EXOZ</a>) shares decreased by 16.82% to $10.49. The company's market cap stands at $99.9 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 16.52% to $0.11. The market value of their outstanding shares is at $2.8 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares fell 16.18% to $0.14. The company's market cap stands at $4.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRVO

EXOZ

NKTX

OSRH

PTPI

SLNO

TNON

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's Intraday Session

Regulus Therapeutics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) released topline results from all patients in the fourth cohort in its Phase&nbsp;1b&nbsp;MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">(ADPKD) on Thursday</a>.
In the fourth cohort, 26 subjects received a fixed dose of 300 mg of farabursen every other <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44510746/regulus-therapeutics-announces-successful-completion-of-its-phase-1b-multiple-ascending-dose-mad-c" rel="noreferrer noopener">week for three months</a>.
ADPKD is caused by mutations in the PKD1 or PKD2 genes, resulting in end-stage renal disease.
The disease is characterized by the development of multiple fluid-filled cysts, primarily in the kidneys.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37613775/why-is-kidney-disease-focused-regulus-therapeutics-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?</a>
The full cohort of 26 patients demonstrated a similar mechanistic response based on urinary PC1 and PC2 levels (which inversely correlate with disease severity) and mean halting of htTKV (which inversely correlates with kidney function) growth over the four-month study period.
Cohort 4 data highlights:
<ul>
<li>Increases in urinary PC1 and PC2 levels were similar to cohort 3 and reached a similar level of statistical significance compared to placebo (PC1 p=0.026; PC2 p=0.014).</li>
<li>The mean htTKV growth rate over 4 months was 0.05%, while placebo subjects in the trial experienced a mean growth rate of 2.58%.</li>
<li>Changes in htTKV were highly correlated with changes in renal cyst volume, suggesting farabursen directly impacts disease progression by limiting abnormal cyst growth.</li>
</ul>
An exploratory analysis compared the combination of patients treated with 3 mg/kg or 300 mg fixed dose faburden (n=35) to a combined historical control group of placebo-treated patients from prior pivotal ADPKD trials (n=550).
Farabursen-treated patients experienced a mean reduction in htTKV growth rate (-0.14%) compared to a mean increase of (+1.87%) in placebo-treated patients (p=0.0056).
Farabursen at 300 mg demonstrated a favorable safety and tolerability profile in this study, consistent with earlier cohorts.
RGLS Price Action: Regulus Therapeutics stock is up 51.94% at $1.96 at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44513286/softbank-may-want-to-outdo-microsoft-with-40-billion-investment-in-openais-latest-funding-round" target="_blank" rel="noreferrer noopener">SoftBank May Want To Outdo Microsoft With $40 Billion Investment in OpenAI&#8217;s Latest Funding Round</a></li>
</ul>
Photo: Shutterstock

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease

Regulus Therapeutics shares are trading higher after the company announced topline results from the phase 1b MAD study of Farabursen for autosomal dominant polycystic kidney disease.

<h3>Gainers</h3>
<ul>
<li>Soleno Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNO#NASDAQ">SLNO</a>) shares increased by 38.8% to $67.98 during Thursday's pre-market session. The company's market cap stands at $2.9 billion. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares moved upwards by 23.05% to $0.1. The market value of their outstanding shares is at $14.4 million. </li>
<li>Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) shares increased by 20.48% to $2.47. The market value of their outstanding shares is at $91.6 million. As per the press release, Q4 earnings came out today. </li>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares moved upwards by 16.36% to $1.28. The company's market cap stands at $6.9 million. </li>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) stock rose 16.27% to $1.5. The market value of their outstanding shares is at $99.3 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 15.94% to $0.12. The company's market cap stands at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock decreased by 21.9% to $2.96 during Thursday's pre-market session. The market value of their outstanding shares is at $57.0 million. </li>
<li>Equillium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQ#NASDAQ">EQ</a>) shares declined by 20.85% to $0.6. The market value of their outstanding shares is at $21.2 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock fell 11.19% to $0.12. The market value of their outstanding shares is at $3.0 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares fell 10.09% to $2.62. The market value of their outstanding shares is at $2.8 million. </li>
<li>Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) shares declined by 10.04% to $0.41. The company's market cap stands at $15.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) stock decreased by 8.39% to $1.42. The company's market cap stands at $58.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANEB

EDAP

HSCS

LPTX

OCEA

ONCO

XTLB

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<ul>
<li>Consistent demonstration of&nbsp;polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney exposure</li>
<li>Patients receiving 300 mg&nbsp;farabursen demonstrated a mean halting of height-adjusted total kidney volume (htTKV) growth over 4 months</li>
<li>Exploratory analysis of patients from high-dose cohorts demonstrates statistical significance in&nbsp;htTKV change compared to a large cohort of historical placebo-treated patients, which meaningfully derisks the 12-month htTKV endpoint in the planned Phase 3 trial</li>
<li>Company on track for initiation of Phase 3 single pivotal trial in third quarter 2025</li>
</ul>

Regulus Therapeutics Announced Topline Results From All Patients In The Fourth Cohort In Its Phase 1b MAD Study Of Farabursen For Autosomal Dominant Polycystic Kidney Disease

Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy and maintains $28 price target.

Canaccord Genuity Maintains Buy on Regulus Therapeutics, Maintains $28 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy and maintains $10 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.76 percent. This is a 50 percent increase over losses of $(0.40) per share from the same period last year.

Earnings Beats

Regulus Therapeutics Q4 2024 GAAP EPS $(0.20) Beats $(0.21) Estimate

Press Releases

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS

Comments

Regulus Therapeutics

Notizie

Ultime notizie per Regulus Therapeutics (NASDAQ:RGLS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO